Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Follow-Up Questions
Who is the CEO of Liquidia Corp?
Dr. Roger Jeffs is the Chief Executive Officer of Liquidia Corp, joining the firm since 2020.
What is the price performance of LQDA stock?
The current price of LQDA is $24, it has increased 0.94% in the last trading day.
What are the primary business themes or industries for Liquidia Corp?
Liquidia Corp belongs to Pharmaceuticals industry and the sector is Health Care
What is Liquidia Corp market cap?
Liquidia Corp's current market cap is $2.0B
Is Liquidia Corp a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Liquidia Corp, including 6 strong buy, 7 buy, 1 hold, 0 sell, and 6 strong sell
